Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 7/20 | 0.67 |
| ▸ | TOP2B | Q02880 | 7/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3983933 | 0.86 | TOP2A (0.67) | TOP2ATOP2BMAPTKMT2ANPSR1 | |
| SCHEMBL3987359 | 0.84 | TOP2A (0.64) | TOP2ATOP2BMEN1MAPTKMT2A | |
| SCHEMBL9300052 | 0.83 | TOP2A (0.73) | TOP2ATOP2BMEN1MAPTRAB9A | |
| SCHEMBL4904565 | 0.82 | TOP2A (0.59) | TOP2ATOP2BMAPTKMT2ANPSR1 | |
| SCHEMBL3983034 | 0.81 | TOP2A (0.77) | TOP2ATOP2BMAPTKMT2ANPSR1 | |
| SCHEMBL9302060 | 0.81 | TOP2A (0.76) | TOP2ATOP2BMAPTKMT2ANPSR1 | |
| SCHEMBL3984609 | 0.80 | TOP2A (0.74) | TOP2ATOP2BMAPTKMT2ANPSR1 | |
| SCHEMBL9301385 | 0.79 | TOP2A (0.69) | TOP2ATOP2BMEN1MAPTKMT2A | |
| SCHEMBL5404447 | 0.79 | TOP2A (0.66) | TOP2ATOP2BMAPTKMT2ANPSR1 | |
| SCHEMBL3989825 | 0.79 | TOP2A (0.66) | TOP2ATOP2BMAPTKMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1380574-B1 | 9-aminoacridine derivates and process for the preparation thereof | SAMJIN PHARM CO LTD (KR) | 2009-05-20 | — | — | EP | disclosed |
| EP-1380574-A1 | 9-aminoacridine derivates and process for the preparation thereof | Samjin Pharmaceutical Co., Ltd. (KR) | 2004-01-14 | — | — | EP | disclosed |
| US-6620936-B2 | Antitumor agents, topoisomerase inhibitors, notoxic | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2003-09-16 | — | — | US | disclosed |
| US-20020111491-A1 | 9-aminoacridine derivatives and process for the preparation thereof | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2002-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111491-A1 | 9-aminoacridine derivatives and process for the preparation thereof | ALKBH1, ADCY9, CCR9 | TOP2A 1105/4885TOP2B 841/4885MEN1 1879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.